BridgeBio Pharma, Inc.(BBIO) Stock Research - Grey Stern Research

BridgeBio Pharma, Inc. (BBIO) Stock Analysis

$26.66 (-1.62%)

BBIO Financial Performance


Use the table below to view BridgeBio Pharma, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $26.66 -
52 Week Low $21.62 -
52 Week High $44.32 -
Market Cap $5.0 Billion 7/16
Gross Margin 78% 9/16
Profit Margin -100% 14/16
EBITDA margin -5112% 15/16
Q3 - 2024 Revenue $2.7 Million 9/16
Q3 - 2024 Earnings -$162.0 Million 16/16
Q3 - 2024 Free Cash Flow -$182.3 Million 16/16
Trailing 4 Quarters Revenue $217.8 Million 6/16
Trailing 4 Quarters Earnings -$438.9 Million 12/16
Quarterly Earnings Growth 8% 8/16
Annual Earnings Growth 33% 7/16
Quarterly Revenue Growth -33% 15/16
Annual Revenue Growth 2316% 1/16
Cash On Hand $266.3 Million 8/16
Short Term Debt $4.6 Million 5/16
Long Term Debt $1.7 Billion 1/16

BridgeBio Pharma, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare BridgeBio Pharma, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/16
PS 23.14 6/16
PB 0.00 15/16
PC 18.92 5/16
Liabilities to Equity 0.00 15/16
ROA -0.66 15/16
ROE 0.36 2/16
Current Ratio 0.35 16/16
Quick Ratio 0.14 16/16
Long Term Debt to Equity -1.40 16/16
Debt to Equity -1.41 16/16
Burn Rate 1.15 10/16
Cash to Cap 0.05 12/16
CCR 1.13 2/16
EV to EBITDA -46.56 10/16
EV to Revenue 29.86 5/16

Company Details

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

CEO: Dr. Neil Kumar

Website: https://www.bridgebio.com

Address: 421 Kipling St Palo Alto, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

BridgeBio Pharma, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to BridgeBio Pharma, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Mirati Therapeutics, Inc. MRTX $4.1 Billion
Madrigal Pharmaceuticals, Inc. MDGL $6.8 Billion
PTC Therapeutics, Inc. PTCT $3.7 Billion
Blueprint Medicines Corporation BPMC $6.0 Billion
Apellis Pharmaceuticals, Inc. APLS $4.2 Billion
Krystal Biotech, Inc. KRYS $5.2 Billion
IVERIC bio, Inc. ISEE $5.5 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
X4 Pharmaceuticals, Inc. XFOR $66.3 Million
Inozyme Pharma, Inc. INZY $159.3 Million
Cerevel Therapeutics Holdings, Inc. CERE $8.2 Billion
Terns Pharmaceuticals, Inc. TERN $547.0 Million
Day One Biopharmaceuticals, Inc. DAWN $1.4 Billion
Acumen Pharmaceuticals, Inc. ABOS $127.4 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
BBIO Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 2.7 Million -$162.0 Million
Q2 2024 $ 2.2 Million -$73.5 Million
Q1 2024 $ 211.1 Million -$35.2 Million
Q4 2023 $ 1.7 Million -$168.1 Million
Q3 2023 $ 4.1 Million -$177.0 Million
Q2 2023 $ 1.6 Million -$157.9 Million
Q1 2023 $ 1.8 Million -$176.8 Million
Q4 2022 $ 1.9 Million -$156.0 Million

View All

BBIO Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $266.3 Million $665.0 Million $1.7 Billion -$1.2 Billion
Q2 2024 $547.4 Million $794.4 Million $1.7 Billion -$1.1 Billion
Q1 2024 $475.4 Million $849.3 Million $1.7 Billion -$1.0 Billion
Q4 2023 $375.9 Million $546.4 Million $1.7 Billion -$1.3 Billion
Q3 2023 $505.2 Million $655.0 Million $1.7 Billion -$1.2 Billion
Q2 2023 $302.4 Million $503.7 Million $1.7 Billion -$1.4 Billion
Q1 2023 $407.4 Million $625.7 Million $1.7 Billion -$1.2 Billion
Q4 2022 $376.7 Million $623.0 Million $1.7 Billion -$1.3 Billion

View All

BBIO Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$182.3 Million -$1.7 Million -$141.6 Million
Q2 2024 $72.3 Million -$2.4 Million $72.0 Million
Q1 2024 -$221.0 Million -$1.5 Million $82.8 Million
Q4 2023 -$125.3 Million -$435,000 -$129.4 Million
Q3 2023 -$145.7 Million -$431,000 $199.5 Million
Q2 2023 -$113.8 Million -$428,000 -$110.5 Million
Q1 2023 -$144.3 Million -$12,000 $18.2 Million
Q4 2022 -$94.0 Million -$801,000 -$68.9 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions